CRMD

CorMedix Inc.

Price Chart

Latest Quote

$8.67

+0.00 (+0.00%)

Current Price

Previous Close	$8.67
Open	$8.84
Day High	$8.84
Day Low	$8.65
Volume	2,511,947

Fetched: 2026-06-19T03:52:36

Stock Information

Shares Outstanding	78.45M
Total Debt	$147.42M
Cash Equivalents	$178.09M
Revenue	$400.05M
Net Income	$180.02M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$680.18M
P/E Ratio	4.00
EPS (TTM)	$2.17
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$649.51M
Sales	$400.05M
Income	$180.02M
Book/sh	$5.58
Cash/sh	$2.27
Employees	191

Financial Ratios

Quick Ratio	2.58
Current Ratio	2.98
Debt/Eq	33.73
EPS Growth TTM	87.00%

Returns & Margins

ROA	26.40%
ROE	65.59%
Gross Margin	91.86%
Operating Margin	49.96%
Profit Margin	45.25%

Ownership

Insider Ownership	7.53%
Institutional Ownership	54.92%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	24.77
P/S	1.70
P/B	1.56

Analyst Data

Recommendation	buy
Target Price	$15.20

Technical Indicators

SMA20	$8.48
SMA50	$7.95
SMA200	$9.16
RSI	56.08
ATR	0.3093

Shares Float	66.53M
Short Float	18.79%
Short Ratio	10.70
Volatility	1.47
Rel Volume	2.02

Performance History

Week	-3.24%
Month	+10.87%
Quarter	+37.62%
6 Months	-24.21%
YTD	-28.70%
Year	-37.80%
3 Years	+51.31%
5 Years	+5.35%
10 Years	-22.93%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$8.67	2,521,900
2026-06-17	$8.67	1,189,000
2026-06-16	$8.66	847,400
2026-06-15	$8.59	1,412,500
2026-06-12	$8.74	968,800
2026-06-11	$8.96	1,237,900
2026-06-10	$8.77	1,316,700
2026-06-09	$8.65	1,412,800
2026-06-08	$8.54	1,773,900
2026-06-05	$8.36	906,200
2026-06-04	$8.54	1,446,800
2026-06-03	$8.23	835,800
2026-06-02	$8.17	964,200
2026-06-01	$8.45	1,196,300
2026-05-29	$8.44	1,041,300
2026-05-28	$8.42	1,287,300
2026-05-27	$8.46	1,088,300
2026-05-26	$8.27	1,313,200
2026-05-22	$7.98	825,900
2026-05-21	$8.06	1,386,200
2026-05-20	$7.93	1,418,600
2026-05-19	$7.82	1,737,200

About CorMedix Inc.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

📰 Latest News

CorMedix (CRMD) Stock Could Be 27.8% Undervalued After Q1 Results And Raised Outlook

Simply Wall St. • 2026-06-17T11:12:17Z

The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath Momentum - Learn Why

Simply Wall St. • 2026-06-16T06:12:31Z

CorMedix Inc. (CRMD) Reports Q1 2026 Results

Insider Monkey • 2026-06-13T18:07:24Z

CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms

MarketBeat • 2026-05-22T10:04:51Z

Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)?

Simply Wall St. • 2026-05-17T19:08:33Z

A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year Guidance

Simply Wall St. • 2026-05-16T12:11:51Z

CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised

Zacks • 2026-05-15T14:11:00Z

Cormedix Inc (CRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com • 2026-05-14T23:02:27Z

CorMedix Inc. Q1 2026 Earnings Call Summary

Moby • 2026-05-14T20:45:30Z

CorMedix (CRMD) Q1 2026 Earnings Transcript

Motley Fool • 2026-05-14T18:44:47Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$35,961,000	$3,190,000	$0	$3,734
Cost Of Revenue	$35,961,000	$3,190,000	$0	$3,734
Total Revenue	$311,709,000	$43,472,000	$0	$65,408
Operating Revenue	$311,709,000	$43,472,000	$0	$65,408
Expenses
Interest Expense	$2,782,000	$36,000	$34,296	$26,515
Total Expenses	$161,568,000	$65,828,000	$48,957,788	$30,689,376
Other Income Expense	$-1,189,000	$488,000	$-28,994	$37,145
Net Non Operating Interest Income Expense	$1,064,000	$2,543,000	$2,647,555	$299,501
Interest Expense Non Operating	$2,782,000	$36,000	$34,296	$26,515
Operating Expense	$125,607,000	$62,638,000	$48,957,788	$30,685,642
Selling And Marketing Expense	$38,054,000	$28,737,000	$18,115,313	-
General And Administrative Expense	$68,220,000	$29,959,000	$17,687,350	-
Other Non Operating Income Expenses	-	$519,000	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$163,055,000	$-17,930,000	$-46,339,227	$-29,701,705
Net Interest Income	$1,064,000	$2,543,000	$2,647,555	$299,501
Interest Income	$3,846,000	$2,579,000	$2,681,851	$326,016
Normalized Income	$163,994,310	$-17,901,232	$-46,310,233	$-29,738,144
Net Income From Continuing And Discontinued Operation	$163,055,000	$-17,930,000	$-46,339,227	$-29,701,705
Total Operating Income As Reported	$150,141,000	$-22,356,000	$-48,957,788	$-30,623,968
Net Income Common Stockholders	$162,067,000	$-17,930,000	$-46,339,227	$-29,701,705
Net Income	$163,055,000	$-17,930,000	$-46,339,227	$-29,701,705
Net Income Including Noncontrolling Interests	$163,055,000	$-17,930,000	$-46,339,227	$-29,701,705
Net Income Continuous Operations	$163,055,000	$-17,930,000	$-46,339,227	$-29,701,705
Pretax Income	$150,016,000	$-19,325,000	$-46,339,227	$-30,287,322
Special Income Charges	$-6,501,000	$0	-	-
Interest Income Non Operating	$3,846,000	$2,579,000	$2,681,851	$326,016
Operating Income	$150,141,000	$-22,356,000	$-48,957,788	$-30,623,968
Gross Profit	$275,748,000	$40,282,000	$0	$61,674
Per Share
Diluted EPS	$2.04	$-0.30	$-0.91	$-0.74
Basic EPS	$2.25	$-0.30	$-0.91	$-0.74
Other
Tax Effect Of Unusual Items	$-249,690	$-2,232	$0	$706
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$168,536,000	$-18,948,000	$-46,205,182	$-30,213,334
Total Unusual Items	$-1,189,000	$-31,000	$-28,994	$37,145
Total Unusual Items Excluding Goodwill	$-1,189,000	$-31,000	$-28,994	$37,145
Reconciled Depreciation	$14,549,000	$310,000	$70,755	$84,618
EBITDA (Bullshit earnings)	$167,347,000	$-18,979,000	$-46,234,176	$-30,176,189
EBIT	$152,798,000	$-19,289,000	$-46,304,931	$-30,260,807
Diluted Average Shares	$80,308,000	$58,871,582	$50,902,931	$40,274,273
Basic Average Shares	$72,034,000	$58,871,582	$50,902,931	$40,274,273
Diluted NI Availto Com Stockholders	$162,067,000	$-17,930,000	$-46,339,227	$-29,701,705
Otherunder Preferred Stock Dividend	$988,000	$0	-	-
Tax Provision	$-13,039,000	$-1,395,000	$0	$-585,617
Restructuring And Mergern Acquisition	$6,501,000	$0	-	-
Gain On Sale Of Security	$5,312,000	$-31,000	$-28,994	$37,145
Research And Development	$19,333,000	$3,942,000	$13,155,125	$10,679,549
Selling General And Administration	$106,274,000	$58,696,000	$35,802,663	$20,006,093
Other Gand A	$68,220,000	$29,959,000	$17,687,350	-

Fetched: 2026-06-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-3,767,000	$82,813,000	$70,142,429	$55,059,736
Total Assets	$826,142,000	$118,846,000	$82,059,957	$62,038,259
Total Non Current Assets	$459,091,000	$4,271,000	$2,609,557	$2,487,084
Other Non Current Assets	$423,000	$105,000	$103,055	$102,320
Non Current Prepaid Assets	$13,029,000	$0	-	-
Non Current Deferred Assets	$16,276,000	$0	-	-
Non Current Deferred Taxes Assets	$16,276,000	$0	-	-
Non Current Accounts Receivable	$946,000	-	-	-
Investmentin Financial Assets	$10,364,000	$0	-	-
Goodwill And Other Intangible Assets	$409,074,000	$1,844,000	$0	-
Other Intangible Assets	$379,072,000	$1,844,000	-	-
Current Assets	$367,051,000	$114,575,000	$79,450,400	$59,551,175
Other Current Assets	$7,861,000	$2,594,000	$882,214	$623,672
Restricted Cash	$656,000	$0	$77,453	$124,102
Prepaid Assets	$9,054,000	$1,039,000	$353,574	$11,016
Inventory	$29,716,000	$7,600,000	$2,106,345	$0
Receivables	$171,233,000	$51,654,000	$0	$0
Accounts Receivable	$171,233,000	$51,654,000	$0	$0
Allowance For Doubtful Accounts Receivable	$-615,000	$-137,000	-	-
Gross Accounts Receivable	$171,848,000	$51,791,000	-	-
Cash Cash Equivalents And Short Term Investments	$148,531,000	$51,688,000	$76,030,814	$58,792,385
Cash And Cash Equivalents	$144,837,000	$40,651,000	$43,642,684	$43,148,323
Debt
Total Debt	$148,914,000	$517,000	$667,632	$802,433
Long Term Debt And Capital Lease Obligation	$147,465,000	$349,000	$517,013	$667,632
Long Term Debt	$144,626,000	-	-	-
Current Debt And Capital Lease Obligation	$1,449,000	$168,000	$150,619	$134,801
Liabilities
Total Liabilities Net Minority Interest	$420,835,000	$34,189,000	$11,917,528	$6,978,523
Total Non Current Liabilities Net Minority Interest	$246,566,000	$349,000	$517,013	$667,632
Other Non Current Liabilities	$99,101,000	-	-	-
Current Liabilities	$174,269,000	$33,840,000	$11,400,515	$6,310,891
Other Current Liabilities	$5,308,000	$124,000	$146,324	$64,456
Payables And Accrued Expenses	$167,512,000	$33,548,000	$11,103,572	$6,111,634
Interest Payable	$2,332,000	$0	-	-
Payables	$21,446,000	$3,720,000	$4,279,679	$2,202,149
Other Payable	$804,000	$2,000,000	-	-
Total Tax Payable	$12,758,000	$0	-	-
Income Tax Payable	$12,758,000	$0	-	-
Accounts Payable	$7,884,000	$1,720,000	$4,279,679	$2,202,149
Equity
Common Stock Equity	$405,307,000	$84,657,000	$70,142,247	$55,059,554
Total Equity Gross Minority Interest	$405,307,000	$84,657,000	$70,142,429	$55,059,736
Stockholders Equity	$405,307,000	$84,657,000	$70,142,429	$55,059,736
Gains Losses Not Affecting Retained Earnings	$3,000	$91,000	$94,108	$82,743
Other Equity Adjustments	$3,000	$91,000	$94,108	$82,743
Retained Earnings	$-176,575,000	$-339,630,000	$-321,700,013	$-275,360,786
Preferred Stock Equity	-	$137	$182	$182
Other
Preferred Shares Number	$45,000	$45,000	$89,999	$89,999
Ordinary Shares Number	$79,260,667	$64,411,295	$54,938,258	$42,815,196
Share Issued	$79,260,667	$64,411,295	$54,938,258	$42,815,196
Tangible Book Value	$-3,767,000	$82,813,000	$70,142,247	$55,059,554
Invested Capital	$549,933,000	$84,657,000	$70,142,247	$55,059,554
Working Capital	$192,782,000	$80,735,000	$68,049,885	$53,240,284
Capital Lease Obligations	$4,288,000	$517,000	$667,632	$802,433
Total Capitalization	$549,933,000	$84,657,000	$70,142,429	$55,059,736
Additional Paid In Capital	$581,800,000	$424,132,000	$391,693,214	$330,294,782
Capital Stock	$79,000	$64,000	$55,120	$42,997
Common Stock	$79,000	$64,000	$54,938	$42,815
Preferred Stock	$0	$0	$182	$182
Long Term Capital Lease Obligation	$2,839,000	$349,000	$517,013	$667,632
Current Capital Lease Obligation	$1,449,000	$168,000	$150,619	$134,801
Current Accrued Expenses	$146,066,000	$29,828,000	$6,823,893	$3,909,485
Investments And Advances	$10,364,000	$0	-	-
Available For Sale Securities	$10,364,000	-	-	-
Goodwill	$30,002,000	$0	-	-
Net PPE	$8,979,000	$2,322,000	$2,506,502	$2,384,764
Gross PPE	$8,979,000	$2,322,000	$3,027,502	$2,834,551
Other Properties	$8,979,000	$2,322,000	$3,027,502	$2,834,551
Finished Goods	$14,390,000	$2,961,000	$0	$0
Work In Process	$11,691,000	$3,528,000	$580,925	$0
Raw Materials	$3,635,000	$1,111,000	$1,525,420	$0
Other Short Term Investments	$3,694,000	$11,037,000	$32,388,130	$15,644,062
Accumulated Depreciation	-	$-674,000	$-521,000	$-449,787

Fetched: 2026-06-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$172,786,000	$-50,731,000	$-38,736,780	$-24,576,092
Operating Activities
Operating Cash Flow	$175,046,000	$-50,615,000	$-38,409,480	$-24,356,732
Cash Flow From Continuing Operating Activities	$175,046,000	$-50,615,000	$-38,409,480	$-24,356,732
Operating Gains Losses	$-86,000	-	-	-
Investing Activities
Capital Expenditure	$-2,260,000	$-116,000	$-327,300	$-219,360
Investing Cash Flow	$-308,430,000	$21,231,000	$-17,061,685	$-3,709,364
Cash Flow From Continuing Investing Activities	$-308,430,000	$21,231,000	$-17,061,685	$-3,709,364
Financing Activities
Issuance Of Capital Stock	$90,158,000	$18,882,000	$55,827,509	$17,769,616
Financing Cash Flow	$238,453,000	$26,319,000	$55,916,804	$17,898,241
Cash Flow From Continuing Financing Activities	$238,453,000	$26,319,000	$55,916,804	$17,898,241
Net Other Financing Charges	$-8,094,000	$-290,000	$-198,443	-
Net Common Stock Issuance	$90,158,000	$18,882,000	$55,827,509	$17,769,616
Common Stock Issuance	$90,158,000	$18,882,000	$55,827,509	$17,769,616
Other
Issuance Of Debt	$150,000,000	$0	-	-
Interest Paid Supplemental Data	$17,000	$36,000	$34,296	$26,516
End Cash Position	$145,825,000	$40,756,000	$43,823,192	$43,374,745
Beginning Cash Position	$40,756,000	$43,823,000	$43,374,745	$53,551,277
Effect Of Exchange Rate Changes	$0	$-2,000	$2,808	$-8,677
Changes In Cash	$105,069,000	$-3,065,000	$445,639	$-10,167,855
Proceeds From Stock Option Exercised	$6,389,000	$7,727,000	$287,738	$128,625
Net Issuance Payments Of Debt	$150,000,000	$0	-	-
Net Long Term Debt Issuance	$150,000,000	$0	-	-
Long Term Debt Issuance	$150,000,000	$0	-	-
Net Investment Purchase And Sale	$2,341,000	$21,347,000	$-16,734,385	$-3,490,004
Sale Of Investment	$55,293,000	$48,116,000	$60,350,000	$27,650,000
Purchase Of Investment	$-52,952,000	$-26,769,000	$-77,084,385	$-31,140,004
Net Business Purchase And Sale	$-308,511,000	$0	-	-
Purchase Of Business	$-308,511,000	$0	-	-
Net PPE Purchase And Sale	$-2,260,000	$-116,000	$-327,300	$-219,360
Purchase Of PPE	$-2,260,000	$-116,000	$-327,300	$-219,360
Change In Working Capital	$7,329,000	$-39,409,000	$2,230,434	$1,066,415
Change In Other Current Liabilities	$-308,000	$-151,000	$-134,801	$-121,368
Change In Payables And Accrued Expense	$104,100,000	$20,425,000	$5,072,563	$955,397
Change In Accrued Expense	$100,771,000	$22,985,000	$2,995,084	$961,963
Change In Payable	$3,329,000	$-2,560,000	$2,077,479	$-6,566
Change In Account Payable	$3,329,000	$-2,560,000	$2,077,479	$-6,566
Change In Prepaid Assets	$-2,061,000	$-2,399,000	$-600,983	$187,235
Change In Inventory	$-3,478,000	$-5,493,000	$-2,106,345	$3,008
Change In Receivables	$-90,924,000	$-51,791,000	$0	$42,143
Changes In Account Receivables	$-90,924,000	$-51,791,000	$0	$42,143
Other Non Cash Items	$7,276,000	$148,000	$134,807	$124,420
Stock Based Compensation	$13,832,000	$6,129,000	$5,493,751	$4,069,520
Unrealized Gain Loss On Investment Securities	$-5,364,000	$0	-	-
Provisionand Write Offof Assets	$252,000	$137,000	$0	-
Deferred Tax	$-25,797,000	$0	-	-
Deferred Income Tax	$-25,797,000	$0	-	-
Depreciation Amortization Depletion	$14,549,000	$310,000	$70,755	$84,618
Depreciation And Amortization	$14,549,000	$310,000	$70,755	$84,618
Amortization Cash Flow	$13,872,000	$156,000	$0	-
Amortization Of Intangibles	$13,872,000	$156,000	$0	-
Depreciation	$677,000	$154,000	$70,755	$84,618
Gain Loss On Sale Of Business	$-86,000	$0	-	-
Net Income From Continuing Operations	$163,055,000	$-17,930,000	$-46,339,227	$-29,701,705

Fetched: 2026-06-17